2024
Design and implementation of a Type-2 hybrid, prospective randomized trial of opioid agonist therapies integration into primary care clinics in Ukraine
Machavariani E, Dumchev K, Pykalo I, Filippovych M, Ivasiy R, Esserman D, Madden L, Bromberg D, Haddad M, Morozova O, Ahmad B, Gómez D, Farnum S, Dvoriak S, Altice F. Design and implementation of a Type-2 hybrid, prospective randomized trial of opioid agonist therapies integration into primary care clinics in Ukraine. Contemporary Clinical Trials 2024, 146: 107690. PMID: 39265780, PMCID: PMC11531372, DOI: 10.1016/j.cct.2024.107690.Peer-Reviewed Original ResearchPrimary care centersQuality health indicatorsNon-communicable diseasesSpecialty treatment centersOpioid agonist therapyImplementation of integrated carePay-for-performance incentivesPrimary care clinicsPrimary care settingSelf-reported prevalencePay-for-performancePrevalence of medical comorbiditiesParticipants self-reportedEffective evidence-based treatmentsHealth of PWIDEvidence-based treatmentsIntegrated careCare clinicsImplementation outcomesImplementation trialCare settingsElectronic chart reviewHigh-burden countriesSpecialty servicesHIV prevalenceThe impact of emergency guidance to the COVID‐19 pandemic on treatment entry, retention and mortality among patients on methadone in Ukraine
Ivasiy R, Madden L, Meteliuk A, Machavariani E, Ahmad B, Zelenev A, Desai M, Bromberg D, Polonsky M, de Leon S, Farnum S, Islam Z, Altice F. The impact of emergency guidance to the COVID‐19 pandemic on treatment entry, retention and mortality among patients on methadone in Ukraine. Addiction 2024, 119: 1585-1596. PMID: 38807448, DOI: 10.1111/add.16565.Peer-Reviewed Original ResearchOpioid agonist therapyTake-home dosesCOVID-19 guidancePre-COVID cohortAgonist therapyOptimal doseTreatment retentionEmergency guidanceEffective HIV prevention strategiesAdult HIV prevalenceHIV prevention strategiesMinistry of HealthImprove treatment retentionMethadone dosePatient survivalTime-dependent predictorsProspective cohortHIV prevalencePredictors of treatment retentionGovernmental clinicsPrimary outcomeHazard ratioPatient enrollmentPatientsMethadone patientsIntegrating methadone into primary care settings in Ukraine: effects on provider stigma and knowledge
Bromberg D, Machavariani E, Madden L, Dumchev K, LaMonaca K, Earnshaw V, Pykalo I, Filippovych M, Haddad M, Dvoriak S, Altice F. Integrating methadone into primary care settings in Ukraine: effects on provider stigma and knowledge. Journal Of The International AIDS Society 2024, 27: e26202. PMID: 38379179, PMCID: PMC10879646, DOI: 10.1002/jia2.26202.Peer-Reviewed Original ResearchConceptsPrimary care clinicsStigma reduction interventionsOpioid agonist therapyClinicians' attitudesStigma constructsHIV preventionReduction interventionsEvidence-based HIV preventionCluster randomized controlled trialEvidence-based carePrimary care settingIntegrated care sitesDirect providersRandomized controlled trialsProvider stigmaCare clinicsCare sitesHIV careCare settingsHealth outcomesClinical staffSubstance use disordersLinear mixed-effects modelsTreatment continuumImprove attitudesPreferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey.
Bromberg D, Madden L, Fraenkel L, Muthulingam D, Rhoades D, Dvoriak S, Dumchev K, Pykalo I, Altice F. Preferences and decisional considerations relating to opioid agonist therapy among Ukrainian people who use drugs: A conjoint analysis survey. PLOS Global Public Health 2024, 4: e0002725. PMID: 38277422, PMCID: PMC10817130, DOI: 10.1371/journal.pgph.0002725.Peer-Reviewed Original ResearchOpioid agonist therapyWithdrawal symptomsAdverse side effectsAgonist therapySide effectsOpioid use disorderQuality-of-life improvementUse disorderCombined HIVHIV incidenceClinical decision-makingDosing frequencyRespondent-driven samplingOpioidOpioid epidemicAssess preferencesClinical concernPatient preferencesPatientsDelivery strategiesTherapyDisordersHIVPatient concernsWithdrawalCorrigendum: High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine
Galvez S, Altice F, Meteliuk A, Ivasiy R, Machavariani E, Farnum S, Fomenko T, Islam Z, Madden L. Corrigendum: High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine. Frontiers In Public Health 2024, 11: 1359708. PMID: 38274528, PMCID: PMC10809844, DOI: 10.3389/fpubh.2023.1359708.Peer-Reviewed Original ResearchStalled Scale-Up of Opioid Agonist Therapies for HIV Prevention in Kazakhstan: History, Policy, and Recommendations for Change
Liberman A, Ivasiy R, Altice F, Bromberg D, Ibragimova O, Seksenova Z, Madden L, Primbetova S, Terlikbayeva A. Stalled Scale-Up of Opioid Agonist Therapies for HIV Prevention in Kazakhstan: History, Policy, and Recommendations for Change. Journal Of Illicit Economies And Development 2024, 5: 69-77. DOI: 10.31389/jied.208.Peer-Reviewed Original Research
2023
High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine
Galvez S, Altice F, Meteliuk A, Ivasiy R, Machavariani E, Farnum S, Fomenko T, Islam Z, Madden L. High perceived stress in patients on opioid agonist therapies during rapid transitional response to the COVID-19 pandemic in Ukraine. Frontiers In Public Health 2023, 11: 1231581. PMID: 38098837, PMCID: PMC10720365, DOI: 10.3389/fpubh.2023.1231581.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderAgonist therapyOAT patientsCOVID-19 pandemicSubstance useTake-home dosingAdditional psychosocial supportHigher perceived stressHigh riskPerceived Stress ScalePsychiatric disordersUse disordersPatientsPatient stressPsychosocial supportCertain subgroupsSevere levelsHigh levelsHealthcare deliveryStress ScalePerceived stressTherapyExtraordinary high levelsDisorders
2021
Successful transfer of stable patients on opioid agonist therapies from specialty addiction treatment to primary care settings in Ukraine: A pilot study
Meteliuk A, Galvez S, Fomenko T, Kalandiia H, Iaryi V, Farnum SO, Islam Z, Altice FL, Madden LM. Successful transfer of stable patients on opioid agonist therapies from specialty addiction treatment to primary care settings in Ukraine: A pilot study. Journal Of Substance Use And Addiction Treatment 2021, 134: 108619. PMID: 34579978, DOI: 10.1016/j.jsat.2021.108619.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyPrimary care clinicsPrimary care settingOAT coverageAgonist therapyStable patientsCare clinicsSubstance useCare settingsNegative urine drug testsSpecialty addictions treatmentUrine drug testsSymptom Identification ScaleMental health symptomsAddiction treatment clinicsHIV transmissionPrimary careTreatment clinicsOAT patientsBASIS-24PatientsHealth symptomsEmotional labilityAddiction treatmentPilot study
2020
Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine
Meteliuk A, Galvez de Leon SJ, Madden LM, Pykalo I, Fomenko T, Filippovych M, Farnum SO, Dvoryak S, Islam ZM, Altice FL. Rapid transitional response to the COVID-19 pandemic by opioid agonist treatment programs in Ukraine. Journal Of Substance Use And Addiction Treatment 2020, 121: 108164. PMID: 33191004, PMCID: PMC7769928, DOI: 10.1016/j.jsat.2020.108164.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyTake-home dosingInterim guidanceShort-term overall mortalityOpioid agonist treatment programPerson clinical encountersOAT deliveryAgonist therapyOverall mortalityCOVID-19 transmissionPatient dropoutOAT patientsNaloxone distributionOverdose educationClinical practiceClinic interactionsTreatment programClinical encountersPatientsCliniciansCOVID-19COVID-19 pandemicOverdosesDosingPrevious yearThe real‐world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine
Farnum SO, Makarenko I, Madden L, Mazhnaya A, Marcus R, Prokhorova T, Bojko MJ, Rozanova J, Dvoriak S, Islam Z, Altice FL. The real‐world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine. Addiction 2020, 116: 83-93. PMID: 32428276, PMCID: PMC7674222, DOI: 10.1111/add.15115.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOAT discontinuationAgonist therapyTreatment retentionIndependent predictorsHIV epidemicCost-effective HIV prevention strategyMethadone maintenance treatment patientsObservational longitudinal cohort studySpecialty addictions treatmentBuprenorphine maintenance treatmentHigh dosageHIV prevention strategiesLongitudinal cohort studyOpioid-dependent peopleTreatment discontinuationCohort studyMaintenance treatmentMale sexTreatment patientsPrevention strategiesDiscontinuationYounger ageCenter settingAddiction treatment
2019
Effect of expanding opioid agonist therapies on the HIV epidemic and mortality in Ukraine: a modelling study
Tan J, Altice FL, Madden LM, Zelenev A. Effect of expanding opioid agonist therapies on the HIV epidemic and mortality in Ukraine: a modelling study. The Lancet HIV 2019, 7: e121-e128. PMID: 31879250, PMCID: PMC7289179, DOI: 10.1016/s2352-3018(19)30373-x.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyNew HIV infectionsHigh HIV burdenHIV infectionMinistry of HealthOAT coverageAgonist therapyHIV burdenHIV incidenceBuprenorphine maintenance therapyPublic Health CenterMaintenance therapyHIV outcomesHIV prevalenceHIV transmissionMedication procurementHIV epidemicHealth centersHIV preventionTreatment goalsPWIDOAT expansionDisease controlSexual riskInfectionElectronic cigarette and tobacco use in individuals entering methadone or buprenorphine treatment
Baldassarri SR, Fiellin DA, Savage ME, Madden LM, Beitel M, Dhingra LK, Fucito L, Camenga D, Bollampally P, Barry DT. Electronic cigarette and tobacco use in individuals entering methadone or buprenorphine treatment. Drug And Alcohol Dependence 2019, 197: 37-41. PMID: 30769264, PMCID: PMC6637405, DOI: 10.1016/j.drugalcdep.2018.12.012.Peer-Reviewed Original ResearchConceptsOpioid use disorderOpioid agonist therapyCurrent cigarette smokingCigarette smokingEC useHigher oddsFormer smokersLower oddsPsychiatric distressPast cigarette smokingElectronic cigarette useAgonist therapyCurrent smokersBuprenorphine treatmentChronic painTobacco useNicotine dependenceUse disordersSmokingCigarette useMultivariate analysisElectronic cigarettesSmokersCigarettesMultivariate model
2018
Assessment of barrier severity and willingness to enter opioid agonist treatment among people who inject drugs in Ukraine
Zelenev A, Shea P, Mazhnaya A, Rozanova J, Madden L, Marcus R, Altice FL. Assessment of barrier severity and willingness to enter opioid agonist treatment among people who inject drugs in Ukraine. Drug And Alcohol Dependence 2018, 190: 82-88. PMID: 29990648, PMCID: PMC6292439, DOI: 10.1016/j.drugalcdep.2018.05.027.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid agonist treatmentOpioid-dependent peopleSubstance abuse treatment programsCross-sectional surveyAgonist therapyAgonist treatmentHIV preventionTreatment perceptionsTreatment efficacyOAT expansionStudy participantsTreatment programAddiction treatmentComposite measureSeveritySocial stigmaDrugsTreatmentStructural barriersBarrier severityParticipants
2017
Using nominal group technique among clinical providers to identify barriers and prioritize solutions to scaling up opioid agonist therapies in Ukraine
Madden L, Bojko MJ, Farnum S, Mazhnaya A, Fomenko T, Marcus R, Barry D, Ivanchuk I, Kolomiets V, Filippovych S, Dvoryak S, Altice FL. Using nominal group technique among clinical providers to identify barriers and prioritize solutions to scaling up opioid agonist therapies in Ukraine. International Journal Of Drug Policy 2017, 49: 48-53. PMID: 28957756, DOI: 10.1016/j.drugpo.2017.07.025.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyNominal group techniqueAgonist therapyBuprenorphine maintenance treatmentAddiction treatment approachesImplementation science strategiesOAT servicesMaintenance treatmentClinical providersTreatment approachesTreatment servicesNGT discussionRegional controlTherapyCliniciansGroup techniqueStructural barriersPatient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine
Marcus R, Makarenko I, Mazhnaya A, Zelenev A, Polonsky M, Madden L, Filippovych S, Dvoriak S, Springer SA, Altice FL. Patient preferences and extended-release naltrexone: A new opportunity to treat opioid use disorders in Ukraine. Drug And Alcohol Dependence 2017, 179: 213-219. PMID: 28806638, PMCID: PMC5599372, DOI: 10.1016/j.drugalcdep.2017.07.010.Peer-Reviewed Original ResearchConceptsOpioid agonist therapyOpioid use disorderExtended-release naltrexoneXR-NTXHIV preventionIndependent correlatesPatient preferencesUse disordersShort-term injectorsPatient-centered treatmentAgonist therapyPharmacological therapyHIV incidenceTreatment optionsPWIDTreatment entryAddiction treatmentPreventionNaltrexoneShort durationTherapyNegative attitudesDisordersNew optionsTreatment